Sio Gene Therapies Inc. (NASDAQ:SIOX – Get Rating) has been given an average rating of “Buy” by the seven research firms that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $5.75.
Several research analysts recently commented on SIOX shares. HC Wainwright dropped their target price on shares of Sio Gene Therapies from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, February 1st. SVB Leerink downgraded shares of Sio Gene Therapies from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $6.00 to $1.00 in a report on Tuesday, February 1st. Finally, Zacks Investment Research upgraded shares of Sio Gene Therapies from a “sell” rating to a “hold” rating in a report on Thursday.
Several large investors have recently bought and sold shares of SIOX. Privium Fund Management UK Ltd bought a new position in shares of Sio Gene Therapies during the 4th quarter worth about $2,367,000. Renaissance Technologies LLC bought a new position in shares of Sio Gene Therapies during the 3rd quarter worth about $1,763,000. Suvretta Capital Management LLC increased its holdings in shares of Sio Gene Therapies by 7.7% during the 4th quarter. Suvretta Capital Management LLC now owns 5,914,000 shares of the company’s stock worth $7,629,000 after purchasing an additional 425,000 shares during the period. BlackRock Inc. increased its holdings in shares of Sio Gene Therapies by 272.9% during the 4th quarter. BlackRock Inc. now owns 530,675 shares of the company’s stock worth $685,000 after purchasing an additional 388,383 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Sio Gene Therapies by 298.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 391,632 shares of the company’s stock worth $850,000 after purchasing an additional 293,348 shares during the period.
Sio Gene Therapies (NASDAQ:SIOX – Get Rating) last released its quarterly earnings results on Friday, February 11th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.09). As a group, equities research analysts anticipate that Sio Gene Therapies will post -0.99 EPS for the current year.
About Sio Gene Therapies (Get Rating)
Sio Gene Therapies, Inc, a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis.
- Get a free copy of the StockNews.com research report on Sio Gene Therapies (SIOX)
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.